Faheem Hasnain - 21 Mar 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Director
Signature
/s/ Teresa Bair, Attorney-in-fact for Faheem Hasnain
Issuer symbol
KURA
Transactions as of
21 Mar 2025
Transactions value $
-$38,106
Form type
4
Filing time
24 Mar 2025, 16:33:39 UTC
Previous filing
06 Mar 2025
Next filing
06 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Options Exercise $143K +22.7K +94.58% $6.32 46.7K 21 Mar 2025 Direct F1
transaction KURA Common Stock Sale -$181K -22.7K -48.61% $8.00 24K 21 Mar 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 20, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $8.00 to $8.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.